Literature DB >> 24339367

Puerarin: a review of pharmacological effects.

Yan-Xi Zhou1, Hong Zhang, Cheng Peng.   

Abstract

Puerarin is the major bioactive ingredient isolated from the root of the Pueraria lobata (Willd.) Ohwi, which is well known as Gegen (Chinese name) in traditional Chinese medicine. As the most abundant secondary metabolite, puerarin was isolated from Gegen in the late 1950s. Since then, its pharmacological properties have been extensively investigated. It is available in common foods and is used in alternative medicine. It has been widely used in the treatment of cardiovascular and cerebrovascular diseases, diabetes and diabetic complications, osteonecrosis, Parkinson's disease, Alzheimer's disease, endometriosis, and cancer. The beneficial effects of puerarin on the various medicinal purposes may be due to its wide spectrum of pharmacological properties such as vasodilation, cardioprotection, neuroprotection, antioxidant, anticancer, antiinflammation, alleviating pain, promoting bone formation, inhibiting alcohol intake, and attenuating insulin resistance. However, the direct molecular mechanisms and targets remain unclear. This review provides a comprehensive summary of the pharmacological effects of puerarin.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Pueraria lobata; pharmacology; puerarin

Mesh:

Substances:

Year:  2013        PMID: 24339367     DOI: 10.1002/ptr.5083

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  124 in total

1.  Puerarin Attenuates LPS-Induced Inflammatory Responses and Oxidative Stress Injury in Human Umbilical Vein Endothelial Cells through Mitochondrial Quality Control.

Authors:  Xing Chang; Tian Zhang; Dong Liu; Qingyan Meng; Peizheng Yan; Duosheng Luo; Xue Wang; XiuTeng Zhou
Journal:  Oxid Med Cell Longev       Date:  2021-02-27       Impact factor: 6.543

2.  Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model.

Authors:  Huan Xu; Mengying Hu; Mengrui Liu; Sai An; Kaiyun Guan; Menglin Wang; Lei Li; Jing Zhang; Jun Li; Leaf Huang
Journal:  Biomaterials       Date:  2020-01-17       Impact factor: 12.479

3.  Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress.

Authors:  Ning Hou; Bin Cai; Cai-Wen Ou; Zhen-Hui Zhang; Xia-Wen Liu; Mu Yuan; Gan-Jian Zhao; Shi-Ming Liu; Long-Gen Xiong; Jian-Dong Luo; Cheng-Feng Luo; Min-Sheng Chen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-16       Impact factor: 3.000

4.  Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway.

Authors:  Xu Ma; Lei Yan; Qing Zhu; Fengmin Shao
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 5.  Membrane-core nanoparticles for cancer nanomedicine.

Authors:  Jianfeng Guo; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-22       Impact factor: 15.470

Review 6.  Puerarin injection for treatment of unstable angina pectoris: a meta-analysis and systematic review.

Authors:  Zhisheng Gao; Baozhu Wei; Cheng Qian
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Puerarin induces cell apoptosis in human chondrosarcoma cell line SW1353 via inhibition of the PI3K/Akt signaling pathway.

Authors:  Li Huang; Junqing Cao; Lan Cao; Ling Gao; Ying Yang; Li Xu
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

Review 8.  Risks and benefits related to alimentary exposure to xenoestrogens.

Authors:  Ilaria Paterni; Carlotta Granchi; Filippo Minutolo
Journal:  Crit Rev Food Sci Nutr       Date:  2017-11-02       Impact factor: 11.176

9.  Small Molecule Regulators of Ferroptosis.

Authors:  Sylvain Debieu; Stéphanie Solier; Ludovic Colombeau; Antoine Versini; Fabien Sindikubwabo; Alison Forrester; Sebastian Müller; Tatiana Cañeque; Raphaël Rodriguez
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Puerarin and betahistine treatment of vertebrobasilar ischemia vertigo: A meta-analysis of randomized controlled trials.

Authors:  Yan-Yan Chen; Wen Chen; Qing Zhang; Hui Li; Ye-Wen Zhang; Qian Kang; Y I Lan; Qing Wu
Journal:  Exp Ther Med       Date:  2016-01-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.